Kopran Limited

KOPRAN

INE082A01010

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:49 28/05/2024 pm IST			5-day change	1st Jan Change
232 ^INR	-1.49%		-4.68%	-3.91%

16/05	Kopran Limited Has Recommends Dividend for the Financial Year Ended March 31, 2024	CI
16/05	Kopran Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

Kopran Limited Announces Board Appointments

May 29, 2018 at 08:53 pm IST

Kopran Limited announced at its board meeting held on May 29, 2018, appointed Mr. Adarsh Somani as an Additional Director of the company with effect from May 29, 2018. The board also appointed Mr. Varun Somani as an additional director of the company with effect from May 29, 2018.

Latest news about Kopran Limited

Kopran Limited Has Recommends Dividend for the Financial Year Ended March 31, 2024	16/05	CI
Kopran Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	16/05	CI
Kopran Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	07/02	CI
Kopran Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	07/11	CI
Kopran Limited Announces Renewal of Gmp Compliance Certificate by Medicines & Healthcare Products Regulatory Agency of United Kingdom (Mhra - Uk)	01/23/01	CI
Crisil Retains BBB+ Rating on Kopran's Bank Loans; Revises Outlook to Negative	18/23/18	MT
Kopran Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	10/23/10	CI
Kopran Limited Recommends Dividend for the Year Ended March 31, 2023	25/23/25	CI
Kopran Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	25/23/25	CI
Crisil Keeps BBB+ Rating on Kopran's Bank Loans; Outlook Stable	26/23/26	MT
Kopran Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	10/23/10	CI
Kopran Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	11/22/11	CI
Kopran Arm Acquires Active Pharmaceutical Ingredient Manufacturing Unit Assets in India	31/22/31	MT
Kopran Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	10/22/10	CI
Kopran Limited Recommends Dividend for the Financial Year 2021-2022	27/22/27	CI
Kopran Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	27/22/27	CI
Kopran Limited Reports Earnings Results for the Full Year Ended March 31, 2022	27/22/27	CI
Crisil Retains BBB+ Rating on Kopran's Bank Loans; Outlook Stable	20/22/20	MT
Kopran Invests Over $13 Million in Subsidiary	21/22/21	MT
Kopran Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	03/22/03	CI
Kopran Limited announced that it has received INR 1.264799745 billion in funding from Mahima STOCKS Private Limited, MC Jain Infoservices Private Limited, United Shippers Limited, Oricon Enterprises Limited	12/22/12	CI
Pharmaceuticals Manufacturer Kopran's Arm Gets New Patent in India	13/21/13	MT
Kopran Limited announced that it expects to receive INR 1.264799745 billion in funding from Mahima Stocks Pvt Ltd, MC Jain Infoservices Private Limited, United Shippers Limited, Oricon Enterprises Limited and other investors	08/21/08	CI
Kopran's Board to Consider Issuance of Equity Shares	03/21/03	MT
Kopran Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	27/21/27	CI

Chart Kopran Limited

Duration

Period

More charts

Company Profile

Kopran Limited is an India-based integrated pharmaceutical company. The Company is primarily engaged in the business of manufacturing of formulation (finished dosage form) and active pharmaceutical ingredients (APIs). Its formulations product categories include penicillin-based finished oral dosage forms and non-penicillin-based finished oral dosage forms. The Company's penicillin-based finished oral dosage forms include anti-infective, amoxycillin, ampicillin, cloxacillin and amoxy clauv. Its non-penicillin-based finished oral dosage forms include macrolides, anti-hypertensive, cardiovascular, anti-helmentics, antihistamine, anti-diabetic, pain management and gastroenterology. It provides ingredients in a wide range of pharmaceutical products, such as capsules, injectables and tablets, among others. The Company's APIs products include anti-hypertensive, macrolides, neuromodulator, urological, anti-infective/anti-acne, sterile carbapenems and sterile cephalosporins.

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
KOPRAN LIMITED	-3.91%	137M
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+31.69%	594B
JOHNSON & JOHNSON	-6.23%	354B
MERCK & CO., INC.	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+14.72%	243B
NOVARTIS AG	+7.66%	205B
ROCHE HOLDING AG	-6.05%	203B
AMGEN INC.	+6.19%	164B